DBV Technologies S.A. cotiza a 9.55 USD y tiene una capitalización bursátil de $600M. En los últimos 12 meses ha facturado $5M con un margen de flujo de caja libre del -2159.6%. Datos fundamentales de la SEC EDGAR con hasta 20 años de histórico, insiders, institucionales y valoración DCF.Más empresas del sector Salud
DBV Technologies S.A., a clinical-stage biopharmaceutical company, engages in the research and development of epicutaneous immunotherapy products in France. Its product pipeline comprising Viaskin Peanut, an immunotherapy product, which has completed Phase 3 clinical trial for the treatment of peanut allergies; and Via…
| Periodo | 2026-10 | 2026-07 | 2026-04 | 2026-03 |
|---|---|---|---|---|
| Real | — | $-0.10 | $-0.09 | $-0.20 |
| Estimado | $-0.15 | $-0.09 | $-0.12 | $-0.19 |
| Sorpresa | — | -11.1% | +25.0% | -5.3% |
| Métrica | DBVT | Mediana Sector | Δ |
|---|---|---|---|
| Gross Margin | — | 57.0% | — |
| Operating Margin | -2609.2% | -38.6% | -2570.6% |
| Net Margin | -2607.3% | -33.6% | -2573.7% |
| FCF Margin | -2159.6% | -13.9% | -2145.7% |
| ROE | -87.1% | -40.4% | -46.7% |
| ROA | -62.9% | -32.0% | -30.9% |
| Current Ratio | 3.67 | 2.84 | +0.83 |
| Debt / Equity | — | 0.28 | — |